News & Updates
Filter by Specialty:
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
08 Nov 2023Women face heightened breast cancer risk from poor air quality
Prolonged exposure to air pollution appears to put women at increased risk of breast cancer, according to data from the French E3N cohort.
Women face heightened breast cancer risk from poor air quality
07 Nov 2023Placebo effect delivers in open-angle glaucoma
Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.
Placebo effect delivers in open-angle glaucoma
07 Nov 2023Diabetes, obesity tied to upstaging in renal cell carcinoma
Diabetes and higher body mass index (BMI) contribute to pathological upstaging in renal cell carcinoma, according to a study. Preoperative tumour size, increased age, and male sex are also significantly associated with upstaging.
Diabetes, obesity tied to upstaging in renal cell carcinoma
07 Nov 2023Synbiotic supplementation of high-fibre diet promising for weight loss
An open-label, randomized, parallel-design clinical trial demonstrates weight loss as well as decreases in fasting glucose, insulin and insulin resistance in overweight and obese Hong Kong Chinese individuals after high-fibre dietary intervention supplemented with synbiotics.
Synbiotic supplementation of high-fibre diet promising for weight loss
07 Nov 2023Surgery offers moderate visual recovery in primary congenital glaucoma
Combined trabeculectomy with trabeculectomy (CTT) confers benefits on patients with primary congenital glaucoma (PCG), suggests a study.
Surgery offers moderate visual recovery in primary congenital glaucoma
06 Nov 2023Rosuvastatin on par with atorvastatin in CAD
Rosuvastatin is as effective as atorvastatin for the composite outcome of all-cause death, myocardial infarction (MI), stroke, or any coronary revascularization at 3 years in adults with coronary artery disease (CAD), according to the secondary analysis of the LODESTAR trial.
Rosuvastatin on par with atorvastatin in CAD
06 Nov 2023Does intermittent fasting reduce acid exposure in GERD patients?
Patients with suspected gastroesophageal reflux disease (GERD) may find it difficult to follow a time-restricted eating, reports a study. Additionally, there is weak evidence to suggest that intermittent fasting helps ease acid exposure.